Alloreactive effector T cell specific for donor alloantigens (Alloreactive T cell)

Alloreactive effector T cells are a specialized subset of T lymphocytes that recognize non-self major histocompatibility complex (MHC) molecules or minor histocompatibility antigens presented by donor tissues (Nature Reviews Immunology, 2017). These cells are the primary mediators of the adaptive immune response in organ transplantation and hematopoietic stem cell transfer, leading to graft rejection or graft-versus-host disease (GVHD) (StatPearls: Transplant Rejection, 2023). Upon activation via the T-cell receptor (TCR) and costimulatory signals, they undergo clonal expansion and differentiate into effector cells that cause tissue damage through the secretion of perforins, granzymes, and pro-inflammatory cytokines like IFN-gamma and TNF-alpha (NIH: Immune Response to Allografts, 2021). Modern immunosuppressive therapy, including calcineurin inhibitors like tacrolimus and costimulation blockers like belatacept, aims to selectively inhibit or deplete these alloreactive populations to promote graft tolerance (PubChem: Tacrolimus; FDA: Belatacept). Understanding the TCR specificity and metabolic requirements of these cells is crucial for developing more targeted, less toxic therapies (American Journal of Transplantation, 2021).

Other names

Donor-specific T cellAlloreactive T lymphocyteGraft-reactive T cellAlloantigen-specific T cellHost-versus-graft T cell

Drugs targeting these cells act by inhibiting calcineurin to prevent IL-2 production, blocking the mTOR pathway to stop cell cycle progression, antagonizing the IL-2 receptor, or providing costimulatory blockade to induce anergy. Additionally, lymphocyte-depleting antibodies can directly eliminate these cells through lysis or apoptosis (StatPearls, 2023; PubChem, 2024).